Related Experiment Video
Updated: Mar 30, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
MAT-1, a monoclonal antibody that specifically recognizes human tyrosinase
H Takimoto1, S Suzuki, S Masui
1Department of Dermal Research, POLA R&D Laboratories, Yokohama, Japan.
Researchers developed a new monoclonal antibody, MAT-1, that specifically recognizes human tyrosinase. This antibody is valuable for studying pigmentary disorders and melanoma diagnosis.
Area of Science:
- Biochemistry
- Immunology
- Dermatology
Background:
- Human tyrosinase is crucial for melanin production.
- Existing monoclonal antibodies lack specificity for human tyrosinase.
Purpose of the Study:
- To produce a specific monoclonal antibody for human tyrosinase.
- To evaluate the antibody's utility in research and diagnostics.
Main Methods:
- Generated a monoclonal antibody (MAT-1) using a synthetic peptide immunogen.
- Determined the epitope of MAT-1.
- Validated antibody specificity using transient expression assays, immunofluorescence, and immunohistochemistry.
Main Results:
- MAT-1 specifically recognizes human tyrosinase.
- The antibody's epitope (EDYH) is unique and not found in related proteins (TRP-1, TRP-2).
- MAT-1 demonstrated specificity for epidermal melanocytes in human skin.
Conclusions:
- MAT-1 is a valuable tool for studying tyrosinase interactions and expression.
- MAT-1 can be used for investigating pigmentary disorders and potentially diagnosing melanoma.
More Related Videos
08:53In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
13:21Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples
Published on: May 4, 2012
Related Concept Videos
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Targeted Cancer Therapies
There are several types of targeted therapies against...